Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

New research from CSHL scientists suggests that cigarette smoke spurs the lungs to make more ACE2 (angiotensin-converting enzyme 2), the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells. The findings, reported May 16, 2020 in the journal Developmental Cell, may explain why smokers appear to be particularly vulnerable to severe infections. The analysis also indicates that the change is reversible, suggesting that quitting smoking might reduce the risk of a severe coronavirus infection.

Patients infected with either severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 produce antibodies that bind to the other coronavirus, but the cross-reactive antibodies are not cross protective, at least in cell-culture experiments, researchers report May 17 in the journal Cell Reports. It remains unclear whether such antibodies offer cross protection in the human body or potentiate disease. The findings suggest that more research is needed to identify parts of the virus that are critical for inducing a cross-protective immune response.

Recruitment for Pharmacists (08 posts) under NHM
18 May 2020
Recruitment for Pharmacists (08 posts) under NHM

Application are invited for Pharmacist under National Health Mission, Malegaon Municipal Corporation for handling corona virus (Covid-19) the outbreak  situation.

Post : Pharmacist

IIHMR University Organize a Webinar on Caring for Women and Children: Post COVID Career Prospects and Professional Pathways
18 May 2020
IIHMR University Organize a Webinar on Caring for Women and Children: Post COVID Career Prospects and Professional Pathways

IIHMR University is a specialized research University in management research, postgraduate education and training in the health sector. The University aims to generate new knowledge and technologies to provide evidence and inputs for developing effective policies and health interventions and strategies.

The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofi’s Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD). Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s.

Bristol Myers Squibb announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Career for Medical Writer at MakroCare
17 May 2020
Career for Medical Writer at MakroCare

MakroCare Expert Strategic Development and Commercialization Global Partner for Pharmaceutical, Biotechnology and Medical Device industries. Our Experience, Programs and Processes bring a New Dimension to Development Strategy, Regulatory/Risk Planning & Management, Clinical Research, Medical/Scientific Support and Emerging Region Expansion.

Post : WFH Medical Writers

No of posts : 02

Recruitment for Pharmacy graduates (11 posts) at GAU | Salary upto Rs 92,300/- pm
13 May 2020
Recruitment for Pharmacy graduates (11 posts) at GAU | Salary upto Rs 92,300/- pm

This prompted the assembly of Gujarat State to pass legislation on 17.12.1965 to establish a University named as Gujarat Ayurveda University with its head quarter in Jamnagar. This University came in existence on January 5th, 1967 with Institute for Post Graduate Teaching & Research and other Ayurvedic Colleges of Gujarat State as affiliated colleges.

Openings for Freshers M.Pharm, M.Sc, B.Pharm at UMEDICA Laboratories
13 May 2020
Openings for Freshers M.Pharm, M.Sc, B.Pharm at UMEDICA Laboratories

UMEDICA is a part of the Amoli Group of Companies, manufacturing and exporting a wide range of formulations viz; Injectables, Tablets, Capsules, Suspensions, Dry Syrups, etc. UMEDICA offers a diverse product portfolio comprising of antibiotics, non-steroidal anti-inflammatory (NSAIDs), analgesics, antifungal, antiviral, anti-malarials, antituberculosis agents, antihistaminics, psychotropic, antihypertensives, lipid-lowering agents, drugs for sexual dysfunction, multivitamins etc.

Vacancy for Project Scientist, Project Assistant at AIIMS
13 May 2020
Vacancy for Project Scientist, Project Assistant at AIIMS

All-India Institute of Medical Sciences was established as an institution of national importance by an Act of Parliament with the objects to develop patterns of teaching in Undergraduate and Post-graduate Medical Education in all its branches so as to demonstrate a high standard of Medical Education in India; to bring together in one place educational facilities of the highest order for the training of personnel in all important branches of health activity; and to attain self-sufficiency in Post-graduate Medical Education.

Recruitment for Research Associate at IISER
13 May 2020
Recruitment for Research Associate at IISER

Indian Institute of Science Education and Research Pune is a premier autonomous Institution established by the Ministry of Human Resource Development, Government of India, for promotion of high quality science education and research in the country.

Institute invites applications from Indian nationals having excellent academic record and relevant work experience for the following position purely on temporary and contractual basis under the funded project.

Post : Research Associate (RA)

Faculty Recruitment in Sarojini Ramulamma College of Pharmacy
13 May 2020
Faculty Recruitment in Sarojini Ramulamma College of Pharmacy

Smt. Sarojini Ramulamma College of Pharmacy (SSRCP), Mahbubnagar welcomes you to the Academic World of Pharmacy. Sri. Dr P Balaraj founder Chairman of  “Dr. Panuganti Krishnamurthy Memorial Educational Society” in the year 1997 and Smt. Sarojini Ramulamma College of Pharmacy is established in the Academic year 1997-98 with a Goal of promoting precision Pharmacist to cater the needs of Pharmacy. SSRCP is a leading Education Institute in Telangana state. The institute caters students to opt for B.Pharm, Pharm D, M.Pharm and D.Pharm courses. The College is producing Highly Qualified Human Resources, Academically Superior and Ethically Strong with the Innovative Concepts and Skills.

The eligible and interested candidate can apply for the following positions.

Post : Professor / Assoc. Professor / Assistant Professor

Job opening for B.Pharm, M.Pharm as Associate Drug Safety Team Lead at Bioclinica
13 May 2020
Job opening for B.Pharm, M.Pharm as Associate Drug Safety Team Lead at Bioclinica

Bioclinica is utilizing data and technology to enable more efficient trial conduct. We are looking at ways to reduce the size of the trials, provide greater clarity into the effect of the drug, and to reduce the amount of complexity in the trial. We do this by improving trial design and utilizing advanced analytics to identify patients who would be high responders for a particular clinical trial.

Post : Associate Drug Safety Team Lead

Job for Pharmacy graduates as Clinical Research Associate at Novo Nordisk
13 May 2020
Job for Pharmacy graduates as Clinical Research Associate at Novo Nordisk

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).

Post : Clinical Research Associate

Opportunity for M.Pharm, B.Pharm as Team Leader at Wipro Limited
13 May 2020
Opportunity for M.Pharm, B.Pharm as Team Leader at Wipro Limited

At Wipro, the safety, health and wellbeing of our employees is of paramount importance and over the past several weeks we have taken a series of preventive measures to protect our employees from the Coronavirus outbreak. Given the evolving situation, we have advised our employees to work from home wherever feasible and if their role allows them to do so. Wipro offices will remain open. Our global Environment, Health & Safety (EHS) and crisis management teams will continue to assess the situation, review these measures after a week and decide the future course of action.

Post : Team Leader B1 level

Require Process Engineer at Pfizer | Bachelors / Masters in Pharmacy
13 May 2020
Require Process Engineer at Pfizer | Bachelors / Masters in Pharmacy

Pfizer is the world's premier biopharmaceutical company taking new approaches to better health.  We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support.

Post : Process Engineer (Visual inspection)

The Council of Scientific and Industrial Research (CSIR), through its New Millennium Indian Technology Leadership Initiative (NMITLI) program, has approved a project towards development of human monoclonal antibodies (hmAbs) that can neutralize SARS-CoV-2 in patients. This project on generation of neutralizing human monoclonal antibodies as a therapeutic strategy will be implemented by a multi-institutional and multi-disciplinary team.

Monoclonal antibody therapy is a form of immunotherapy designed to produce immunity to a disease or to enhance resistance by the immune system. This new project aims to generate hmAbs to SARS-CoV-2 from gradual recovery phase of COVID-19 patients and select high affinity and neutralizing antibodies. The project also aims to anticipate future adaptation of the virus and generate hmAbs clones that can neutralize the mutated virus so that could be readily used for combating future SARS-CoV infections.

This new project aims to generate hmAbs to SARS-CoV-2 from gradual recovery phase of COVID-19 patients and select high affinity and neutralizing antibodies.

This industry-academia collaboration comprises National Centre for Cell Science (NCCS) Pune; Indian Institute of Technology (IIT), Indore; PredOmix Technologies Ltd, Gurugram; and Bharat Biotech International Ltd (BBIL), Hyderabad. Vaccines and biotherapeutics maker BBIL is leading the project to develop human monoclonal antibodies (hmAbs) for COVID-19 infection. BBIL will be the commercial partner and responsible for subsequent development and commercialization of the hmAbs generated.

DG-CSIR, Dr Shekhar C Mande commented that “As the research into SARS-CoV-2 is in early days and our understanding is evolving each day, it is critical that we deploy all possible strategies to combat the virus. Hence, CSIR is exploring all avenues and we are supporting new ideas which have clear deployment strategy”.

CSIR is leading the fight against COVID-19 using multi-pronged approach and multiple models of engagement. CSIR labs themselves are developing technologies and products and are working with industry and public sector undertakings for deployment. NMITLI is a flagship program of CSIR aimed to support new ideas and projects from academic institutions and industries.


- India Science Wire

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

Cipla Limited announced that it has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine Remdesivir, which has been issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat COVID-19 patients. This agreement is part of Cipla’s efforts to enhance global access to life-saving treatments for patients affected by the pandemic.

As part of the agreement, Cipla will be permitted to manufacture the API and Finished product, and market it in 127 countries including India and South Africa under Cipla’s own brand name. Cipla will receive the manufacturing know-how from Gilead Sciences, Inc. to manufacture the API and Finished product at a commercial scale. Cipla’s extensive geographical and commercial footprint will help make this therapy accessible to more patients and markets.

According to the World Health Organisation (WHO)’s tracker, the number of reported COVID-19 cases has crossed the four million mark globally.

The EUA will facilitate broader use of Remdesivir to treat hospitalized patients with severe symptoms of COVID-19. The EUA is based on available data from two global clinical trials – US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead’s global Phase 3 study evaluating Remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of Remdesivir as a potential treatment for COVID-19. Remdesivir continues to be an investigational drug that has not been approved by the FDA.

Commenting on the partnership, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, “As the world is faced with the COVID-19 crisis, it is imperative that we collaborate and fight this virus together. We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals. At Cipla, it is our continuous endeavour to ensure that no patient is denied access to life-saving treatments. Our partnership with Gilead represents this unwavering commitment and is a significant step towards saving millions of lives impacted by the pandemic.”

<< Back to Pharma News


Subscribe to PharmaTutor News Alerts by Email

Subscribe to